



ADVANSOURCE BIOMATERIALS SUBMITS PLAN TO NYSE AMEX

Wilmington, MA. September 17, 2010... AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced it has submitted a plan advising the NYSE Amex of the actions it has taken and will take to bring the Company into compliance with certain listing standards of the NYSE Amex by February 17, 2012. The plan was submitted to the NYSE Amex on September 16, 2010 in response to a previous notification that the Company was not in compliance with the continued listing standards of Section 1003(a)(iii) of the NYSE Amex's Company Guide. The Company intends to issue a follow-up press release once it receives notification from the NYSE Amex as to the status of acceptance of the plan. The Company's common stock continues to be listed on the NYSE Amex under the ticker symbol "ASB."

About AdvanSource Biomaterials Corporation

AdvanSource Biomaterials Corporation manufactures advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. The Company's business model leverages its proprietary materials science technology and manufacturing expertise in order to expand its product sales and royalty and license fee income. More information about the Company is available at its website: www.advbiomaterials.com

Forward-Looking Statements

AdvanSource believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. For further information on such risks and uncertainties, you are encouraged to review AdvanSource's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2010 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, and press releases issued subsequent to our filing of our June 30, 2010 Form 10-Q. AdvanSource assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

For further information contact:

AdvanSource Biomaterials Corporation

David Volpe, Acting CFO
(978) 657-0075, ext. 103
dvolpe@advbiomaterials.com

